Literature DB >> 23242124

Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease.

Mohamad A Alsadany1, Hanan H Shehata, Magda I Mohamad, Riham G Mahfouz.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive abilities. Epigenetic modification, oxidative stress, and inflammation play an important role in the pathogenesis of the disease. We aimed to detect noninvasive peripheral biomarkers with a high degree of sensitivity and specificity in diagnosis and progression of AD.
METHODS: A total of 25 elderly patients with AD and 25 healthy control participants were selected and subjected to cognitive assessment and laboratory measures including histone deacetylases (HDACs), copper, and interleukin 8 (IL-8) levels.
RESULTS: The levels of HDACs, copper, and IL-8 were significantly higher in patients with AD (P < .001) and had a significant negative effect on all cognitive assessment tests. Receiver-operating curve (ROC) analysis revealed that HDACs and copper levels had higher sensitivity and specificity.
CONCLUSIONS: Plasma levels of HDACs and copper may be used as peripheral biomarkers in diagnosis of AD, while IL-8 level could be a useful biomarker in following AD progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242124     DOI: 10.1177/1533317512467680

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  26 in total

Review 1.  Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease.

Authors:  Heather M Wilkins; Russell H Swerdlow
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 2.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

3.  Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease.

Authors:  John A McIntyre; Curtis J Ramsey; Bruce D Gitter; Andrew J Saykin; Dawn R Wagenknecht; Paul A Hyslop
Journal:  Autoimmunity       Date:  2015-02-12       Impact factor: 2.815

Review 4.  The Roles of Histone Modifications in Metal-Induced Neurological Disorders.

Authors:  Yingying Wu; Ruike Wang; Rundong Liu; Yue Ba; Hui Huang
Journal:  Biol Trace Elem Res       Date:  2022-02-07       Impact factor: 3.738

Review 5.  Glial biomarkers in human central nervous system disease.

Authors:  Gwenn A Garden; Brian M Campbell
Journal:  Glia       Date:  2016-05-26       Impact factor: 7.452

6.  Increased inflammation in BA21 brain tissue from African Americans with Alzheimer's disease.

Authors:  Sherry A Ferguson; Vijayalakshmi Varma; Daniel Sloper; John J Panos; Sumit Sarkar
Journal:  Metab Brain Dis       Date:  2019-12-10       Impact factor: 3.584

Review 7.  TDO as a therapeutic target in brain diseases.

Authors:  Cheng-Peng Yu; Ze-Zheng Pan; Da-Ya Luo
Journal:  Metab Brain Dis       Date:  2016-04-13       Impact factor: 3.584

Review 8.  Kynurenines in CNS disease: regulation by inflammatory cytokines.

Authors:  Brian M Campbell; Erik Charych; Anna W Lee; Thomas Möller
Journal:  Front Neurosci       Date:  2014-02-06       Impact factor: 4.677

Review 9.  Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection.

Authors:  Heather M Wilkins; Steven M Carl; Alison C S Greenlief; Barry W Festoff; Russell H Swerdlow
Journal:  Front Aging Neurosci       Date:  2014-11-10       Impact factor: 5.750

Review 10.  Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases.

Authors:  Hueng-Chuen Fan; Ching-Shiang Chi; Shin-Nan Cheng; Hsiu-Fen Lee; Jeng-Dau Tsai; Shinn-Zong Lin; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2015-12-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.